ClinicalTrials.gg
RecruitingNCT06998524WILL-EMIUpdated Nov 16, 2026

A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease

A Phase 3 interventional study of Emicizumab and von Willebrand Factor (VWF) Concentrates in Von Willebrand Disease, Type 3, sponsored by Hoffmann-La Roche. Recruiting at 30 sites in 14 countries. Open to participants aged 1 Month and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.
Updated Nov 16, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
1 Month and older
Sex
All
01

Study summary

This is a Phase III, multicenter, open-label clinical study designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab prophylaxis in participants aged 1 month and above, who have been diagnosed with Type 3 von Willebrand disease (VWD). Participants on prior standard of care (SOC) on-demand therapy will be assessed via a randomized comparison (Arm A - emicizumab prophylaxis and Arm B - continuation of SOC on-demand therapy), while participants on prior SOC prophylactic therapy (Arm C - emicizumab prophylaxis) will be assessed via intra-participant analysis with data obtained from the preceding non-interventional study (NIS), WP45335 (NCT06883240).

02

Conditions studied

  • Von Willebrand Disease, Type 3
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of Type 3 von Willebrand disease (VWD), based on medical records
  • Preexisting medical record verifying the status of von Willebrand factor (VWF) inhibitor (positive or negative, including titer if available)
  • Adequate hematologic, hepatic, and renal function
  • For participants of : agreement to remain abstinent or adhere to the requirements

Additional Inclusion Criteria for Arms A and B:

  • Age ≥1 month at the time of signing /Assent Form
  • Documented previous use of on-demand therapy with intermittent (less than once a week) on-demand SOC therapy for VWD
  • Having ≥2 treated bleeds (except menstrual bleeds) with factor concentrate within 24 weeks prior to enrollment

Additional Inclusion Criteria for Arm C:

  • Age ≥2 years at the time of signing Informed Consent/Assent Form
  • Documented and confirmed previous use of SOC prophylactic therapy for VWD (1-3 times weekly, as per prescribed dose) as described in the eligibility of Study WP45335
  • Have completed all study requirements as defined in the WP45335 protocol for at least 24 weeks

Exclusion criteria

Exclusion Criteria:

  • Inherited or acquired bleeding disorder other than Congenital Type 3 VWD
  • History of gastrointestinal bleeding within 18 months prior to enrollment, or any previous diagnosis of angiodysplasia
  • History of intracranial hemorrhage
  • Previous or current treatment for thromboembolic disease or signs of thromboembolic disease
  • Other conditions (e.g., certain diseases) that may increase risk of bleeding or thrombosis
  • History of associated with monoclonal antibody therapies or components of the emicizumab injection
  • Use of systemic immunomodulators (e.g., interferon) at enrollment or planned use during the study, with the exception of anti-retroviral therapy
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Arm A (Prior On-Demand SOC): Emicizumab Prophylaxis for 24 Weeks

    Participants who are randomized to Arm A, taking on-demand standard of care (SOC) treatment at the time of study entry (and for at least 24 weeks prior to enrollment), will receive emicizumab SC prophylaxis.

    Drug: Emicizumab

  • Active comparator
    Arm B (Prior On-Demand SOC): On-Demand SOC for 24 Weeks

    Participants who are randomized to Arm B, taking on-demand standard of care (SOC) treatment at the time of study entry (and for at least 24 weeks prior to enrollment), will continue to receive their current SOC on-demand treatment until Week 24.

    Drug: von Willebrand Factor (VWF) Concentrates · Drug: Factor VIII (FVIII) Concentrates · Drug: von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates · Drug: Bypassing Agents

  • Experimental
    Arm C (Prior Prophylaxis SOC): Emicizumab Prophylaxis for 24 Weeks

    Participants who enroll in Arm C, taking SOC prophylactic treatment at the time of study entry and for at least 24 weeks of observation during the preceding NIS WP45335, will receive emicizumab SC prophylaxis.

    Drug: Emicizumab

  • Experimental
    Treatment Extension Period for All Arms: Emicizumab Prophylaxis

    Participants in Arms A and C who have completed 24 weeks of emicizumab prophylaxis and who derive benefit from emicizumab will have the opportunity to continue to receive emicizumab prophylaxis in the extension period. Participants in Arm B who have completed 24 weeks of SOC on-demand treatment will have the opportunity to receive emicizumab prophylaxis in the extension period.

    Drug: Emicizumab

Interventions

  • Participants will receive emicizumab 3 milligrams per kilogram (mg/kg) subcutaneous (SC) injections every week (QW) for the first 4 weeks as loading doses, followed by maintenance doses of emicizumab 3 mg/kg SC once every 2 weeks (Q2W). During the extension period, participants may remain on maintenance dose of emicizumab 3 mg/kg Q2W, or change their emicizumab maintenance regimen to 1.5 mg/kg once every week (QW) or 6 mg/kg once every 4 weeks (Q4W), if they prefer and if agreed by the investigators.

    Also known as: Hemlibra, RO5534262, RG6013

  • Drugvon Willebrand Factor (VWF) Concentrates

    Used according to local labeling or local treatment guidelines.

  • DrugFactor VIII (FVIII) Concentrates

    Drug pages: Factor VIII · Antihemophilic factor, human recombinant

    Used according to local labeling or local treatment guidelines.

  • Drugvon Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates

    Drug pages: Factor VIII · Antihemophilic factor, human recombinant

    Used according to local labeling or local treatment guidelines.

  • DrugBypassing Agents

    Used according to local labeling or local treatment guidelines.

06

What researchers measure

Primary outcomes

  1. Annualized Bleed Rate (ABR) for Treated Bleeds in the Randomized Arms

    Time frame: From Baseline to at least 24 weeks

Secondary outcomes

  1. ABR for All Bleeds in the Randomized Arms

    Time frame: From Baseline to at least 24 weeks

  2. ABR for Treated Spontaneous Bleeds in the Randomized Arms

    Time frame: From Baseline to at least 24 weeks

  3. ABR for Treated Joint Bleeds in the Randomized Arms

    Time frame: From Baseline to at least 24 weeks

  4. Intra-Participant Comparison of the ABR for Treated Bleeds with Prophylactic Emicizumab Versus Prophylactic SOC from the Preceeding Non-Interventional Study (NIS) WP45335

    Time frame: From Baseline to at least 24 weeks

  5. Intra-Participant Comparison of the ABR for All Bleeds with Prophylactic Emicizumab Versus Prophylactic SOC from the Preceeding NIS WP45335

    Time frame: From Baseline to at least 24 weeks

  6. Intra-Participant Comparison of the ABR for Treated Spontaneous Bleeds with Prophylactic Emicizumab Versus Prophylactic SOC from the Preceeding NIS WP45335

    Time frame: From Baseline to at least 24 weeks

  7. Intra-Participant Comparison of the ABR for Treated Joint Bleeds with Prophylactic Emicizumab Versus Prophylactic SOC from the Preceeding NIS WP45335

    Time frame: From Baseline to at least 24 weeks

  8. Incidence and Severity of Adverse Events, with Severity Determined According to the World Health Organization (WHO) Toxicity Grading Scale

    Time frame: From first dose of study treatment until 24 weeks after final dose of study treatment (up to 3 years, 11 months)

  9. Incidence and Severity of Thromboembolic Events

    Time frame: From first dose of study treatment until 24 weeks after final dose of study treatment (up to 3 years, 11 months)

  10. Incidence and Severity of Thrombotic Microangiopathy Events

    Time frame: From first dose of study treatment until 24 weeks after final dose of study treatment (up to 3 years, 11 months)

  11. Incidence and Severity of Injection-Site Reactions

    Time frame: From first dose of study treatment until 24 weeks after final dose of study treatment (up to 3 years, 11 months)

  12. Incidence of Adverse Events Leading to Drug Discontinuation

    Time frame: From first dose of study treatment until 24 weeks after final dose of study treatment (up to 3 years, 11 months)

  13. Incidence of Severe Hypersensitivity, Anaphylaxis, or Anaphylactoid Reactions

    Time frame: From first dose of study treatment until 24 weeks after final dose of study treatment (up to 3 years, 11 months)

  14. Incidence of Clinical Laboratory Abnormalities

    Time frame: From first dose of study treatment until 24 weeks after final dose of study treatment (up to 3 years, 11 months)

  15. Trough Plasma Concentration of Emicizumab at Prespecified Timepoints During the Treatment Period

    Time frame: Predose and at prespecified timepoints from first dose of emicizumab until study completion (up to 3 years, 11 months)

  16. Percentage of Participants with Anti-Drug Antibodies (ADAs) to Emicizumab at Baseline and with ADAs to Emicizumab During the Treatment Period

    Time frame: Baseline and at prespecified timepoints from first dose of emicizumab until study completion (up to 3 years, 11 months)

  17. Change from Baseline in Respiratory Rate Over Time

    Time frame: Baseline, Weeks 1, 2, 25, and every 12 weeks thereafter (weeks after switch to emicizumab for Arm B only) until study completion (up to 3 years, 11 months)

  18. Change from Baseline in Pulse Rate Over Time

    Time frame: Baseline, Weeks 1, 2, 25, and every 12 weeks thereafter (weeks after switch to emicizumab for Arm B only) until study completion (up to 3 years, 11 months)

  19. Change from Baseline in Systolic Blood Pressure Over Time

    Time frame: Baseline, Weeks 1, 2, 25, and every 12 weeks thereafter (weeks after switch to emicizumab for Arm B only) until study completion (up to 3 years, 11 months)

  20. Change from Baseline in Diastolic Blood Pressure Over Time

    Time frame: Baseline, Weeks 1, 2, 25, and every 12 weeks thereafter (weeks after switch to emicizumab for Arm B only) until study completion (up to 3 years, 11 months)

  21. Change from Baseline in Body Temperature Over Time

    Time frame: Baseline, Weeks 1, 2, 25, and every 12 weeks thereafter (weeks after switch to emicizumab for Arm B only) until study completion (up to 3 years, 11 months)

  22. Change from Baseline in Electrocardiogram (ECG) Parameters Over Time: QT, QTcF, RR, PR, and QRS Intervals

    Time frame: Baseline and study completion (up to 3 years, 11 months)

  23. Change from Baseline in Heart Rate Over Time, as Measured by Electrocardiogram (ECG)

    Time frame: Baseline and study completion (up to 3 years, 11 months)

  24. Change from Baseline in the PROMIS-29 Questionnaire Pain Interference Domain Score Over Time

    PROMIS-29 stands for Patient-Reported Outcomes Measurement Information System-29

    Time frame: Baseline and at prespecified timepoints until study completion (up to 3 years, 11 months)

  25. Change from Baseline in the PROMIS-29 Questionnaire Fatigue Domain Score Over Time

    PROMIS-29 stands for Patient-Reported Outcomes Measurement Information System-29

    Time frame: Baseline and at prespecified timepoints until study completion (up to 3 years, 11 months)

07

Study locations

30 of 30 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jun 2025 (actual). Primary completion is estimated for Oct 2027, 27 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Apr 2027 → Oct 2027 and completion Apr 2029 → Sep 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2025
First posted
May 31, 2025
StartActual
Jun 27, 2025
Primary completionEst.
Oct 6, 2027was Apr 2027
CompletionEst.
Sep 6, 2029was Apr 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Queen Elizabeth Hospital · Birmingham, United Kingdom
Nov 12, 2026
Primary completion
Apr 30, 2027→Oct 6, 2027
Nov 16, 2026
Study completion
Apr 30, 2029→Sep 6, 2029
Nov 16, 2026
Show all 3 updates
  1. Nov 16, 2026
    Primary completion Apr 30, 2027→Oct 6, 2027
    Study completion Apr 30, 2029→Sep 6, 2029
  2. Nov 12, 2026
    1 site added
    Show site
    • Queen Elizabeth Hospital · Birmingham, United Kingdom
    + 1 other change: verification date
  3. Oct 9, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06998524
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 31, 2025
Start date
Jun 27, 2025
Primary completion
Oct 6, 2027 (estimated)
Completion
Sep 6, 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Reference Study ID Number: WP45338 https://forpatients.roche.com/
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. Only)
Fastest response: use the inquiry form. No email attachments. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emicizumab

Start the discussion